InvestorsHub Logo
Followers 32
Posts 2803
Boards Moderated 3
Alias Born 10/24/2015

Re: NY1972 post# 189

Saturday, 11/05/2022 2:41:35 PM

Saturday, November 05, 2022 2:41:35 PM

Post# of 386
From memory, the ORRs for anti-CD19 CARs, be they CB, PB or iPSC-derived were similar. However, both PB and iPSC have a major advantage when it comes to large scale expansion. With CB, I think the highest doses (per manufacturing run) are ~100. As for iPSCs, they beat both when it comes to genetic engineering.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News